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Abstract
Bronchodilator response (BDR)is an important asthma phenotype that measures reversibilityof airwayobstruction by comparing
lung function (i.e. FEV1) before and after the administration of a short-acting b2-agonist, the most common rescue medications
used for the treatment of asthma. BDR also serves as a test of b2-agonist efficacy. BDR is a complex trait that is partly under
genetic control. A genome-wide association study (GWAS) of BDR, quantified as percent change in baseline FEV1 after
administration of a b2-agonist, was performed with 1,644 non-Hispanic white asthmatic subjects from six drug clinical trials:
CAMP, LOCCS, LODO, a medication trial conducted by Sepracor, CARE, and ACRN. Data for 469,884 single-nucleotide
polymorphisms (SNPs) were used to measure the association of SNPs with BDR using a linear regression model, while adjusting
for age, sex, and height. Replication of primary P-values was attempted in 501 white subjects from SARP and 550 white subjects
from DAG. Experimental evidence supporting the top gene was obtained via siRNA knockdown and Western blotting analyses.
The lowest overall combined P-value was 9.7E-07 for SNP rs295137, near the SPATS2L gene. Among subjects in the primary
analysis,those with rs295137TT genotypehada medianBDR of16.0 (IQR=[6.2,32.4]),whilethose with CCor TC genotypes hada
median BDR of 10.9 (IQR=[5.0, 22.2]). SPATS2L mRNA knockdown resulted in increased b2-adrenergic receptor levels. Our results
suggest that SPATS2L may be an important regulator of b2-adrenergic receptor down-regulation and that there is promise in
gaining a better understanding of the biological mechanisms of differential response to b2-agonists through GWAS.
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          Introduction
Asthma is a chronic respiratory disease that affects over 20
million Americans and 300 million people worldwide [1,2]. A
hallmark characteristic of asthma is reversible airway obstruction,
which is commonly measured via a bronchodilator response
(BDR) test, in which the reduction of bronchoconstriction after
administration of a short-acting reliever drug is quantified [3]. b2-
agonists, the most common short-acting reliever drugs used during
BDR tests and for asthma therapy, act in part by stimulating b2-
adrenergic receptors (b2ARs) on airway smooth muscle cells to
reduce bronchoconstriction via subsequent increases in cyclic
adenosine monophosphate (cAMP) and protein kinase A (PKA)
[3]. Although a comprehensive pathophysiologic understanding of
BDR has not been obtained, it is a complex trait involving
interactions among various tissues and cells, including inflamma-
tory [4], airway epithelium [5], smooth muscle [6], and the
autonomic nervous system [7]. In addition to being used for the
diagnosis of asthma, BDR tests can be used to measure whether
inhaled b2-agonists are effective in patients. Although short-acting
b2-agonists are widely used clinically as asthma rescue medica-
tions, they are variably efficacious among patients [8]. Studying
BDR may thus provide information regarding both the patho-
physiology and pharmacogenetics of asthma.
The search for genetic variants that modify asthma susceptibility
has resulted in the most recent multi-center asthma genome-wide
association studies (GWAS) providing strong statistical evidence
for the association of many genes, including the IKZF3-ZPBP2-
GSDMB-ORMDL3 locus, HLA-DQ, IL1RL1, IL18RL1, IL33, TSLP,
SLC22A5, SMAD3, and RORA, with asthma [9,10]. Functional
experiments to identify the role that these genes play in asthma
pathophysiology are hindered by the complexity of the asthma
phenotype. Familial aggregation [11] and genetic association
studies [12] have provided suggestive evidence for a genetic
contribution to interindividual differences in BDR. Candidate
genes reported to be associated with BDR include b2-adrenergic
receptor (ADRB2) [13,14], adenylyl cyclase type 9 (ADCY9) [15],
corticotrophin-releasing hormone receptor 2 (CRHR2) [16], and
arginase 1 (ARG1) [17,18]. While BDR is a complex phenotype,
functional studies of BDR candidate genes are simpler than those
for a general asthma phenotype because this pharmacogenetic
phenotype can be readily simulated in vitro via stimulation of cells
with b2-agonists.
In this study, we performed a GWAS of BDR in 1,644 non-
Hispanic white asthmatics and found that the strongest evidence of
association with BDR was at variants near the Homo sapiens
spermatogenesis associated, serine-rich 2-like (SPATS2L) gene. We
attempted to replicate the primary findings in two independent
populations and investigated the function of SPATS2L via mRNA
knockdown experiments and found evidence to support its
involvement in BDR.
Results
Primary BDR GWAS
Figure 1 is an overview of our study design. Characteristics of
the subjects used in the primary GWAS are provided in Table 1.
We utilized 1,644 non-Hispanic white subjects from six clinical
trials to measure the association of SNPs to BDR. After QC filters,
469,884 SNPs genotyped in CAMP/LOCCS/LODO/Sepracor
and either genotyped or imputed in CARE and ACRN were used
to test for the association of SNPs to BDR. We utilized genotyped
SNPs for CAMP/LOCCS/LODO/Sepracor because these co-
horts, who were all genotyped using Illumina platforms, had the
largest sample size. Due to the poor overlap of Illumina and
Affymetrix platform SNPs, we utilized HapMap Phase 2 imputed
SNPs for CARE and ACRN, so that the maximal number of SNPs
in all cohorts could be analyzed. The quantile-quantile (QQ) and
Manhattan plots revealed that the distribution of association P-
values was similar to that expected for a null distribution and that
no P-values met genome-wide statistically significant levels (Figures
S1 and S2). To expand the primary association results further, all
SNPs available in the June 2010 release of the 1000 Genome
Project (1000GP) data were imputed using MaCH in each of the
three primary groups of genotype data and overall BDR GWAS
results were re-computed. Among SNPs contained in the primary
GWAS, imputed and genotyped P-values were similar, particu-
larly for those with low P-values (Figure S3). Some imputed
regions had P-values lower than those of the primary GWAS, but
the results in most of these regions were not supported by primary
GWAS data (Figure S2). Thus, we proceeded to attempt to
validate the primary GWAS findings based on the combined
genotyped CAMP/LOCCS/LODO/Sepracor SNP results and
HapMap Phase 2 imputed CARE and ACRN SNP results. The
top five primary GWAS SNPs with P-value,1E-05 are in Table 2.
Further details on these regions and all primary GWAS SNPs with
P-value,1E-04 are in Tables S1 and S2. Further details on all
1000GP imputed GWAS SNPs with P-value,1E-05 are in Tables
S3 and S4.
Replication of Primary GWAS Findings
We attempted to replicate in SARP all of the SNPs with
primary GWAS P-values,1E-04 (Table S5). Three had nominally
significant P-values (i.e. ,0.05), and two of these associations
supported the top 5 primary GWAS associations (Table 3). The
lowest combined P-value for all primary GWAS plus SARP data
was 7.7E-07 for rs295137. The region of BDR association
spanning this SNP was in the 59UTR region of SPATS2L, a gene
of unknown in vivo function and paralog of SPATS2 (Figure 2). The
effect of the rs295137 genotype on BDR is shown in Figure 3, and
a plot of the residuals of the linear regression fit of BDR while
adjusting for age, sex, and height is shown in Figure S4. We sought
further evidence of association for the two SPATS2L SNPs with
lowest P-values in our primary GWAS in a second independent
population: DAG. There was no evidence for association in this
cohort (rs295137 P-value=0.21; rs295114 P-value=0.21), and
combined P-values for these two SNPs across all cohorts were
Author Summary
Bronchodilator response (BDR) is an important asthma
phenotype that measures reversibility of airway obstruc-
tion by comparing lung function before and after the
administration of short-acting b2-agonists, common med-
ications used for asthma treatment. We performed a
genome-wide association study of BDR with 1,644 white
asthmatic subjects from six drug clinical trials and
attempted to replicate these findings in 1,051 white
subjects from two independent cohorts. The most signif-
icant associated variant was near the SPATS2L gene. We
knocked down SPATS2L mRNA in human airway smooth
muscle cells and found that b2-adrenergic receptor levels
increased, suggesting that SPATS2L may be a regulator of
BDR. Our results highlight the promise of pursuing GWAS
results that do not necessarily reach genome-wide
significance and are an example of how results from
pharmacogenetic GWAS can be studied functionally.
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combined association represented a biologically significant finding,
we sought experimental evidence that SPATS2L was involved in
bronchodilator response.
SPATS2L mRNA Expression Changes when the b2-Agonist
Pathway Is Modified in Human Airway Smooth Muscle
Cells
We found one public gene expression array experiment
(GSE13168) that would help to address the question of whether
SPATS2L is differentially expressed in response to changes in the
BDR pathway. We compared the levels of expression of two
SPATS2L and one SPATS2 probes in human airway smooth
muscle (HASM) cells that stably expressed a PKA inhibitor vs. a
GFP control at baseline and when stimulated with the pro-
asthmatic cytokines interleukin-1b (IL1b), epidermal growth factor
(EGF), or both. A trend of differential expression was observed for
the SPATS2 and one SPATS2L probes, but not a second SPATS2L
probe (Figure S5). None of the comparisons met a Benjamini-
Hochberg adjusted significance threshold, but nominally signifi-
cant P-values were obtained for the SPATS2 probe under all
conditions and for one of the SPATS2L probes under the condition
of EGF and IL1b stimulation (Table S6). According to the Gene
Enrichment Profiler, the two SPATS2L probes are highly expressed
in lung, and all three probes are highly expressed in smooth
muscle, especially the SPATS2 one. Overall, there are strikingly
different tissue-specific expression patterns for each probe (Figure
S6).
Knockdown of SPATS2L mRNA Leads to Increased b2AR
Levels
We further investigated the involvement of SPATS2L in the b2-
adrenergic response pathway by knocking down SPATS2L mRNA
using two different small interfering RNAs (siRNA) and measuring
subsequent changes in b2AR protein levels. The knockdown
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Figure 1. Study overview. (A) Primary GWAS was conducted using
subjects from CAMP, LOCCS, LODO, Sepracor, ACRN, and CARE cohort.
Samples genotyped on Illumina platforms (i.e. CAMP/LOCCS/LODO/
Sepracor) were pooled and analyzed first. Results from samples
genotyped on Affymetrix platforms were analyzed separately and then
combined to obtain the primary GWAS results. 1000GP imputed data
was utilized to expand the primary GWAS association results. (B)
Replication of the top (i.e. P-value,1E-04) SNPs from the primary GWAS
were attempted in two independent populations: SARP and DAG. (C)
The SPATS2L gene was selected for functional validation based on
nominal replication of association results in SARP and analysis of
publicly available resources.
doi:10.1371/journal.pgen.1002824.g001
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PLoS Genetics | www.plosgenetics.org 3 July 2012 | Volume 8 | Issue 7 | e1002824efficiency of the siRNAs was .80% reduction of SPATS2L mRNA
as measured by qRT-PCR, and the corresponding increases in
b2AR (normalized against the control b-actin protein) levels were
1.88- (SD 0.41) and 1.86- (SD 0.30) fold for the two SPATS2L
siRNAs (Figure 4).
Primary GWAS Results in Previously Identified BDR
Candidate Genes
The association of SNPs with BDR at SNPs in/near genes (i.e.
ADRB2, ADCY9, CRHR2, ARG1) previously reported as being
associated with BDR was measured in our primary GWAS
imputed data (Figure S7). Nominally significant (P-value,0.05)
SNPs were found in ADCY9, CRHR2, and ARG1, but not in
ADRB2 (Tables S7 and S8). The SNPs with lowest P-values within
50 kb of these genes were: rs2531988 for ADCY9 (3.2E-03),
rs12533248 for CRHR2 (0.029), and rs6929820 for ARG1 (0.012).
Discussion
In recent years, many GWAS that have successfully identified
risk-modifying loci for a wide range of complex diseases have been
published, but progress toward understanding how the loci and
genes identified are functionally related to diseases has been slow
[19]. The relationship of genes and gene variants to pharmaco-
genetic traits is often easier to test functionally than that for
complex diseases because pharmacogenetic traits are more
amenable to in vitro testing. However, compared to GWAS of
complex diseases, GWAS of pharmacogenetic traits have been
challenged by the relatively small size of drug clinical trials, which
has caused many studies to be underpowered for obtaining
genome-wide significant associations [20]. Nonetheless, successful
pharmacogenetic GWAS have led to the identification of loci
involved in modulating response to inhaled corticosteroids among
asthma patients [21], warfarin dose [22], and lipid-lowering
response to statins [23].
One of the difficulties specific to BDR GWAS is the complexity
of the BDR phenotype. Regardless of how it is quantified, BDR is
highly variable among asthma patients due to the time-dependent
variation in baseline FEV1 and the influence of external
environmental factors [24]. BDR can be quantified in various
ways, with slightly varying resulting classification of patients as
responders or non-responders. For our study, we selected the
definition most widely utilized in clinical and human asthma
research settings: percent change in baseline FEV1 following
administration of a standard dose of short-acting inhaled b2-
agonist [25]. We have attempted to control for the known
relationship between baseline lung function and BDR [24,26] by
(1) selecting a definition of BDR that standardizes the change in
FEV1 by dividing by baseline FEV1 and (2) by using age, sex, and
height, which together account for a large portion of the variability
in baseline lung function, as covariates in our statistical models.
Because BDR tests are routinely performed during asthma clinical
trials to use as inclusion criteria and to monitor outcomes among
patients, we were able to utilize subjects from several diverse
asthma clinical trials that were not specifically designed to study
the pharmacogenetics of BDR. Most of these trials included a
wash-out period that reduces modification of BDR due to
concomitant medication administration, but LOCCS and some
CARE and ACRN subjects were administered BDR tests at a time
when they were not necessarily off of medications (Table 1).
Subjects without a placebo washout, and especially those who
were on ICS (e.g. LOCCS subjects), may be expected to have less
BDR than those on placebo. The relationship of the magnitude of
BDR to the various gene loci could therefore be blunted and show
a less significant relationship than would be expected if all studies
had incorporated a placebo washout.
In addition to variable washout periods, the cohorts had other
significant differences in their design. Two trials consisted of
children with asthma (i.e. CAMP, CARE), while the others
consisted mostly of adults. The gender composition varied from
25% to 62% male. We attempted to control for age, gender and
height, all of which are known to influence BDR, by including
them as covariates in the association analysis. The mean and range
of BDR also varied among trials. Of most significance, because the
Sepracor trial used BDR greater than 15% as a criterion for
Table 2. Primary GWAS Top Results (SNPs with Combined P-values ,1e-05).
CLLS CARE ACRN
SNP CHR BP Minor Allele MAF P-value MAF P-value Rsq MAF P-value Rsq
Combined
P-value Gene
rs4452682 6 3360301 A 0.40 4.80E-05 0.44 0.021 0.89 0.46 0.018 0.79 3.20E-06 SLC22A23
rs295137 2 200858285 T 0.41 4.90E-05 0.41 1.10E-03 0.95 0.41 0.12 0.97 3.40E-06 SPATS2L
rs295114 2 200903847 T 0.43 3.50E-05 0.42 1.50E-03 0.96 0.42 0.42 0.99 6.00E-06 SPATS2L
rs10940113 5 66850598 C 0.37 1.00E-06 0.34 0.73 0.90 0.35 0.72 0.91 6.10E-06
rs4328902 4 25348267 T 0.27 2.20E-05 0.27 0.38 0.73 0.26 0.026 0.78 6.10E-06
CLLS=CAMP/LOCCS/LODO/Sepracor. CLLS used genotyped SNP data. CARE and ACRN used HapMap Phase 2 imputed data with Mach ratio of empirically observed
dosage variance to the expected dosage variance (Rsq) values indicated.
doi:10.1371/journal.pgen.1002824.t002
Table 3. Replication study of top SNPs in two independent
populations (SARP and DAG).
SARP DAG
SNP MAF P-value MAF P-value
Combined
P-value*
rs4452682 0.50 0.43 - - 1.3E-05
rs295137 0.41 0.044 0.40 0.21 9.7E-07
rs295114 0.43 0.043 0.42 0.21 1.6E-06
rs10940113 0.37 0.16 - - 5.5E-06
rs4328902 0.34 0.91 - - 2.8E-04
*rs295137 and rs295114 include SARP and DAG P-values. Remaining SNPs
include SARP only.
doi:10.1371/journal.pgen.1002824.t003
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other trials. We attempted to control for this difference and any
other trial specific differences among the cohorts that were pooled
in the primary analysis by including trial as a covariate in the
association model. There were additional differences among trials
that were not taken into account. For example, SARP and
Sepracor were composed of subjects with more severe asthma than
those of other cohorts. Some ACRN, CARE, and SARP subjects
were administered a different amount of albuterol during their
BDR tests than those of CAMP, Sepracor, LOCCS, and LODO.
DAG subjects were administered a different beta-agonist (i.e.
Salbutamol) at a different concentration than that used with
subjects of all other trials. DAG and SARP subjects were not
participants of clinical trials, so there was greater heterogeneity of
subjects within those cohorts. Despite the heterogeneity among
trials, we utilized as many subjects as possible in an attempt to
increase our statistical power to detect associations of SNPs with
BDR. We reasoned that any associations detected despite the
heterogeneity of the trial populations would be those most likely to
generalize to all asthma patients. Another expected consequence
of the trial heterogeneity is that our association results do not
replicate in all cohorts. While having the largest number of
subjects provides the greatest statistical power to detect statistically
significant associations that are most generalizable across the
clinical trials, we may be missing associations that are specific to
the individual trials. For example, the subjects within clinical trials
representing different ranges of asthma severity, age, and baseline
characteristics may have genetic associations that are unique to
subjects with their specific trial characteristics. The small sample
size of each individual clinical trial makes detection of trial-specific
Figure 3. Summary of BDR by genotype of the SNP (rs295137)
near SPATS2L with lowest P-value among all subjects in the
primary populations. The TT genotype was associated with higher
BDR (median 16.0; inter-quartile range (IQR)=[6.2, 32.4]), than the TC
genotype (median 11.2; IQR=[5.2, 22.6]) or the CC genotype (median
10.3; IQR=[4.1, 21.7]).
doi:10.1371/journal.pgen.1002824.g003
Figure 2. Region of association near SPATS2L SNPs to BDR. The x-axis denotes position along Chromosome 2. The y-axis denotes 2Log10(P)
corresponding to 1000GP imputed data P-values. LD between the SNP with the lowest P-value (rs295137) to each SNP in the plot is denoted in colors
and was computed according to 1000GP June 2010 CEU data. Plot was created using LocusZoom [44].
doi:10.1371/journal.pgen.1002824.g002
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our meta-analysis identified a strong association that suggests a
novel gene is involved in BDR.
Our top association was at SNP rs295137, with a combined P-
value across all cohorts of 9.7E-07. This P-value does not meet
conventional genome-wide significance thresholds (e.g. Bonferroni
corrected minimally significant P-value would be 0.05/
469,884=1.1E-07), but performing searches through public data
sources and the fact that other pharmacogenetic GWAS have
discovered biologically important results without genome-wide
significant associations led us to pursue our top association further.
The region of association surrounding rs295137 is in the 59UTR
of SPATS2L (Figure 2). This gene maps to chromosome 2 at
2q33.1, covering 176.78 kb from 201170592 to 201347368 (NCBI
37, August 2010). According to data gathered via the AceView
[27] tool, SPATS2L is a complex locus that may have at least 30
spliced variants, its in vivo function is unknown, and it is a highly
expressed gene in many tissues, with the greatest number of
GenBank accessions belonging to lung. In gene-trap experiments
in myoblasts, SPATS2L (a.k.a. SGNP) was found to be involved in
ribosomal biogenesis and translational control in response to
oxidative stress [28].
The availability of one public expression array experiment that
utilized HASM cells expressing a PKA inhibitor (PKI) to modify
the b2-adrenergic pathway allowed us to perform a preliminary
search for evidence that SPATS2L may be involved in BDR. We
found that a probe for SPATS2, the paralog of SPATS2L, was
significantly differentially expressed in PKI vs. control cells at
baseline and when stimulated with pro-inflammatory cytokines
(EGF, IL1b, or both). One SPAST2L probe followed this trend but
had a nominally significant P-value only under the condition of
stimulation with both EGF and IL1b, while the other SPATS2L
probe did not exhibit any changes. As illustrated in Figure S6, the
tissue-specific expression patterns of the three probes varied
widely. While all were expressed in smooth muscle, the SPATS2
probe’s relative expression in this tissue was markedly greater than
that of the SPATS2L probes. Taken together, the expression
patterns are consistent with tissue and isoform dependent changes
in SPATS2L gene products. While the public dataset SPATS2L
results were inconclusive based on the differences among probes,
they suggested that SPATS2L expression may change when PKA is
inhibited in HASM cells.
Knockdown of SPATS2L in HASM cells resulted in significantly
increased b2AR protein levels, suggesting that SPATS2L may affect
BDR by directly modulating b2AR protein expression. In HASM,
b2-agonists exert their effects exclusively via the b2AR [6]. The
relaxation of HASM occurs after the binding of b2-agonists to
b2ARs via increased levels of cAMP followed by PKA activation.
PKA activation leads to changes in gene transcription via activation
ofcAMPresponseelement bindingprotein(CREB). Because b2ARs
are the gateway to the effects of b2-agonists in HASM cells,
modulations, such as SPATS2L inactivation, that increase the levels
of b2ARs in HASM cells may lead to both greater relaxation in
response to b2-agonists in the short term and greater differences in
gene transcription in the longer term. Further study is needed to
elucidate the precise mechanismby whichSPATS2L regulates b2AR
and consequently modifies BDR. Among our primary GWAS
subjects, those whose SPATS2L SNP rs295137 has the TT genotype
have greater BDR than those with CT or TT genotypes (median
BDR 16.0 vs. 10.9). In one of the simplest scenarios, it is possible
that the increased BDR among subjects with the TT genotype
results from this genotype playing a direct role in decreasing
transcription of SPATS2L, which in turn results in increased b2AR
levels. Further work is required to understand how specific SNP
associations in/near SPATS2L affect SPATS2L function and/or
expression and how such effects impact b2AR signaling and BDR.
Because the observed influence of our most strongly associated SNP
genotype on BDR is relatively small (Figure 3), our current data do
not support the development of anypersonalized therapeutics based
solely on variants in/near SPATS2L.
In addition to studying top primary GWAS SNPs, we attempted
to replicate findings from previous BDR candidate gene associ-
ation studies. Specifically, we measured association between BDR
and ADRB2 [13,14], ADCY9 [15], CRHR2 [16], and ARG1 [17]
variants. Notably, these previous findings are not entirely
independent of those from the current GWAS: CAMP was a
primary population utilized to identify associations in ADRB2,
ADCY9, CRHR2, and ARG1 in previous reports; LODO and
Sepracor were replication populations in the CRHR2, and ARG1
reports; and LOCCS was a replication population in the ARG1
report. At a nominal significance level, we replicated gene-level
associations for all of the candidate genes other than ADRB2. This
gene, which encodes the b2AR, is the most studied gene related to
BDR and SNPs and haplotypes in this gene have been related to
decreased pulmonary function [29], response to b2-agonist
treatment [30], an increased frequency of asthma exacerbations
Figure 4. Effect of siRNA-mediated SPATS2L knockdown on b2-
adrenergic receptor levels in HASM cells. (A) Knockdown
efficiency of two SPATS2L siRNAs. Quantitative real-time PCR was done
on RNAs extracted from HASM cells transfected with control non-
targeting (NT) or SPATS2L-specific siRNAs. (B) Western blot analysis of
b2AR protein in SPATS2L knockdown HASM cells. Three independent
experiments (siRNA transfection and Western blot analysis) were done
in HASM cells. The upper panel is a representative of the three Western
blots. Quantification of the b2AR protein amount (normalized against
the control b-actin protein) from three Western blots is shown in the
lower panel.
doi:10.1371/journal.pgen.1002824.g004
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very promising and suggested that variants of this candidate gene
would be reliable markers of BDR pharmacogenetics. However, a
meta-analysis of 21 studies of ADRB2 polymorphisms found that
most of the positive associations identified in individual studies
cannot be compared to findings in other studies due to different
study designs, phenotypes considered and selective reporting,
making the number of variants with true replications very small
and questioning the utility of ADRB2 polymorphisms for
generalizable pharmacogenetic tests [32]. Our inability to find
associations with ADRB2 variants is consistent with the view that
BDR genetics are complex: no individual SNPs or genes are
responsible for a large proportion of BDR variability observed
among all asthmatics. Our results suggest that genes other than the
previously identified candidate genes are more strongly associated
with BDR and that functional studies of these regions may yield
important insights into BDR biology despite not having strong
effects or generalizing to all populations.
In summary, a BDR GWAS among asthma patients from eight
cohorts found that the most strongly associated SNP, rs295137,
had a combined P-value of 9.7E-07. This association led us to
SPATS2L, a gene of unknown in vivo function that we showed may
be involved in BDR via the down-regulation of b2AR levels. Our
results support the notion that there is promise in pursuing GWAS
results that do not necessarily reach genome-wide significance and
are an example of the way in which results from pharmacogenetic
GWAS can be studied functionally.
Materials and Methods
Ethics Statement
Each study was approved by the Institutional Review Board of
the corresponding institution, which ensured that all procedures
followed were in accordance with the ethical standards of the
responsible committee on human experimentation. Informed
consent was obtained for all study participants.
Subjects
The primary group of subjects consisted of 1,644 non-Hispanic
white asthmatics from the following drug clinical trials: Childhood
Asthma Management Program(CAMP)[33], Leukotriene Modifier
or Corticosteroid Salmeterol study (LOCCS) [34], Effectiveness of
Low Dose Theophylline as an Add-on Treatment in Asthma trial
(LODO) [35], a medication trial conducted by Sepracor, Inc.
[36,37], and subsets of clinical trials within the Childhood Asthma
Research and Education (CARE) network [38], and the Asthma
Clinical Research Network (ACRN) [39] participating in the
NHLBI SNP Health Association Resource (SHARe) Asthma
Resource project (SHARP). Some basic characteristics of these
cohorts are in Table 1 and further details are provided in Text S1.
BDR tests wereperformed according to American Thoracic Society
criteria with Albuterol as the b2-agonist [25], unless otherwise
noted. Baseline BDR measures were utilized, and BDR was
quantified as the percent change in FEV1 in response to
administration of a b2-agonist [i.e. (post-BD FEV1 – pre-BD
FEV1)/pre-BD FEV1].
Genotyping and Quality Control
Genome-wide genotyping for CAMP subjects (n=546) was
performed on the HumanHap550 Genotyping BeadChip or
Infinium HD Human610-Quad BeadChip by Illumina, Inc (San
Diego, CA) at the Channing Laboratory. LOCCS (n=135),
LODO (n=114), and Sepracor (n=401) subjects were genotyped
at the Riken Center for Genomic Medicine using the Infinium HD
Human610-Quad BeadChip. CARE (n=207) and ACRN
(n=241) subjects were genotyped on Affymetrix 6.0 genotyping
chip by Affymetrix, Inc. (Santa Clara, CA). Data from those
subjects genotyped using Illumina technologies was combined into
a primary dataset with 469,884 overlapping SNPs having
missingness ,1%, passing HWE (P-value threshold of 1E-03),
and having minor allele frequency (MAF).0.05. EIGENSTRAT
was used to identify 23 outliers (not included in counts above)
based on being outside of six standard deviations of the top four
principal components during five iterations [40]. The genomic
inflation factor (lGC) of the remaining 1,196 subjects was 1.002,
demonstrating minimal population stratification. CARE and
ACRN dataset quality control (QC) also included the removal of
four related subjects (i.e. CARE siblings), SNPs with MAF,0.05,
missingness .5%, or not passing HWE based on a threshold of
1E-03. The lGC for CARE and ACRN genotype data were 1.02
and 0.98, demonstrating minimal population stratification among
subjects within each group. Comprehensive genotyping and QC
measures are provided in Text S1.
Statistical Analysis
Due to the poor overlap among SNPs genotyped on the
Illumina and Affymetrix platforms, imputation of all SNPs
available in HapMap Phase 2 Release 22 CEU data using the
Markov Chain Haplotyping software (MaCH) [41] was performed
for ACRN and CARE genotyped data. The primary GWAS
consisted in the set of 469,884 SNPs that were successfully
genotyped in those cohorts using Illumina arrays (i.e., CAMP/
Sepracor/LOCCS/LODO) and imputed with HapMap Phase 2
data in those cohorts genotyped with Affymetrix arrays (i.e.,
ACRN and CARE) with a ratio of empirically observed dosage
variance to the expected (binomial) dosage variance greater than
0.3, indicating good quality of imputation.
To expand the association results, imputation of all SNPs
available in the June 2010 release of the 1000 Genome Project
(1000GP) data using MaCH was performed for each of the three
primary groups of genotype data. An overlapping set of 4,571,615
imputed SNPs had a MAF.0.05 and ratio of empirically observed
dosage variance to the expected (binomial) dosage variance greater
than 0.5, indicating good quality of imputation.
The association of SNPs with BDR was measured with a linear
regression model as implemented in PLINK [42] in the three sets
of data: 1) CAMP/Sepracor/LOCCS/LODO, 2) ACRN, 3)
CARE. Association of imputed SNPs was carried out using dosage
data. Covariates for the CAMP/Sepracor/LOCCS/LODO
group included age, gender, height, and study. Covariates for
the CARE and ACRN groups included age, gender, and height.
To get the primary GWAS results, CARE and ACRN P-values
were combined with those of the CAMP/Sepracor/LOCCS/
LODO group by using Liptak’s combined probability method [43]
where hypothesis tests in CARE and ACRN had one-sided
alternatives, based on the direction of the association in CAMP/
Sepracor/LOCCS/LODO, so that SNPs with association tests in
opposite directions would not produce inappropriately small P-
values. The overall lGC was 1.002 in the primary set of GWAS
results and 1.000 in the 1000GP imputed data GWAS.
Plots of association results near specific genes were created using
LocusZoom with the hg18/1000 Genomes June 2010 CEU
GenomeBuild/LD Population [44].
Replication Studies
1) Severe Asthma Research Program (SARP). Replication
of primary GWAS P-values was attempted in 501 European
American subjects from SARP who were recruited to meet the
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asthmatics, with enrichment for severe asthma [45]. Genotyping
was performed on the Illumina Infinium HD Human 610-Quad
Bead Chip at Wake Forest University. Tests of BDR association
were performed using linear regression in R [46] with age, sex,
and height as covariates.
2) Dutch Asthma GWAS (DAG). Replication of two SNPs
near SPATS2L with lowest P-values in the primary GWAS was
attempted in 550 DAG subjects with asthma and BDR data that
were phenotyped in a single center (i.e, Beatrixoord, Haren, the
Netherlands) [18,47]. All patients refrained from bronchodilator
use for at least 8 hours, and stopped inhaled steroids for 2 weeks
before pulmonary function testing if clinically possible. Revers-
ibility was assessed measuring spirometry before and 15 minutes
after inhaling 800 mg of salbutamol. Genotyping was performed
using the Hapmap 317K platform or Illumina 370 Duo Chip.
Tests of BDR association were performed using linear regression,
with age, gender and height as covariates using Predictive Analysis
Software (PASW) version 18.0.
Genome-Wide Gene Expression Data
The publicly available Gene Expression Omnibus (GEO) dataset,
GSE13168,correspondingtoanexperimentinwhichhumanairway
smooth muscle (HASM) cell cultures were generated from four
donor trachea to test for the effects of glucocorticoids and PKA
inhibitionontheHASMtranscriptomeusingtheAffymetrixHuman
Genome U133A platform was used [48]. We tested for the
involvement of our top primary GWAS gene in the b2-adrenergic
pathway by comparing the differential expression of genes in cells
stably expressing a PKA inhibitor(PKI) vs. control at baseline and in
the presence of pro-inflammatory cytokines interleukin-1b (IL1b),
epidermal growth factor (EGF), or both. The expression array
contained two SPATS2L probes (i.e., 215617_at, 222154_s_at) and
one SPATS2 probe (i.e., 218324_s_at). The probe for the paralog of
SPATS2L was included to account for the possibility of non-specific
binding of SPATS2L mRNA to the SPATS2 probe. Analyses were
conducted in R [46]. Pre-processing of raw signal intensities was
performedwithRMA[49]anddifferentialexpressionwasquantified
using the limma package [50]. Tissue-specific expression of these
probes was assessed using 557 microarrays from 126 human normal
primary tissues in the Gene Enrichment Profiler [51].
SPATS2L siRNA Knockdown and b2AR Western Blotting
Analysis
Primary HASM cells were isolated from aborted lung transplant
donors with no chronic illness. The tissue was obtained from the
National Disease Resource Interchange (NDRI) and their use
approved by the University of Pennsylvania IRB. HASM cell
cultivation and characterization were described previously [52,53].
Passages 4 to 7 HASM cells maintained in Ham’s F12 medium
supplemented with 10% FBS were used in all experiments. 2610
5
HASM cells were grown overnight and then transfected with 50 nM
siRNA by using DharmaFECT 1 reagent (Thermo Scientific,
Lafayette, CO, USA). About 72 h post transfection, cells were
washed with PBS and lysed with NP-40 lysing buffer (50 mM Tris-
HCl pH7.5, 150 mM NaCl,0.5% Nonidet P-40) containing protease
inhibitor cocktail (Roche Diagnostics Corporation, Indianapolis, IN,
USA). Protein samples were denatured 10 min at 50uC, separated on
NuPAGE 4–12% Bis-Tris gels (Invitrogen, Grand Island, NY, USA)
and transferred to PVDF membranes (Bio-Rad Laboratories,
Hercules, CA, USA). Immunoblot signals were developed using
SuperSignal West Pico (Pierce Protein Research Products, Thermo
Fisher Scientific, Rockford, IL, USA) and quantified by ImageJ
software. Non-targeting control siRNA, SPATS2L-specific siRNA 1
(sense59- guc agu cca uug auu guc u(dT)(dT)-39,a n t i s e n s e5 9-a g ac a a
uca aug gac uga c(dT)(dT) -39)a n dSPATS2L- s p e c i f i cs i R N A2( s e n s e
59-caa ccu gug uug uag cag u(dT)(dT)-39, antisense 59-a c ug c ua c a
aca cag guu g(dT)(dT) -39) were obtained from Sigma-Aldrich
(Mission siRNA; St. Louis, MO, USA). Antibodies for b2AR (H20)
and b-actin were from Santa Cruz Biotechnology, Inc. (Santa Cruz,
CA, USA). Experiments were performed in triplicate.
Supporting Information
Figure S1 Quantile–quantile plot. Comparison of primary
GWAS P-values to those expected for a null distribution. There
is little evidence of deviation of measures at the tail, obscuring the
distinction among SNPs having low p-values representing true
associations vs. those SNPs having low p-values by chance.
(TIFF)
Figure S2 Manhattan plot. The x-axis denotes position along
each chromosome. The y-axis denotes 2Log10(P) corresponding
to association P-values. The 1000GP imputed results are in light
blue and green. The primary GWAS results are in dark blue and
green. Some of the lowest imputed P-values did not have
corresponding primary GWAS p-values, while other regions with
low P-values contained both primary and imputed GWAS results.
We prioritized regions based on primary GWAS results.
(TIFF)
Figure S3 P-value comparison between Primary GWAS vs.
1000GP imputed results, for those SNPs contained in both
datasets. The results are highly correlated (r
2=0.99).
(TIFF)
Figure S4 Residuals of linear regression fit of BDR , age + sex
+ height vs. rs295137 genotypes.
(TIFF)
Figure S5 Distribution of normalized signal intensities across
different experimental conditions for two SPATS2L and one
SPATS2 probes corresponding to a subset of GSE13168 arrays
where the effects of protein kinase A inhibition (PKI) in human
airway smooth muscle cells was assessed at baseline and following
stimulation with epidermal growth factor (EGF), interleukin 1 beta
(IL1b), or both. Corresponding P-values and log-Fold Change
differences are in Table S4. A) SPATS2 probe 218324_s_at, B)
SPATS2L probe 215617_at, C) SPATS2L probe 222154_s_at.
(TIF)
Figure S6 Tissue-specific gene expression patterns of Affy
U133A probes for SPATS2 and SPATS2L (a.k.a. LOC26010).
(TIFF)
Figure S7 Plots of imputed association results near previously
identified BDR candidate genes. A) ADCY9,B )ADRB2 C) ARG1,
D) CRHR2.
(TIFF)
Table S1 Primary GWAS SNP details for SNPs with Primary
GWAS P,1E-04.
(DOCX)
Table S2 Primary GWAS P-values and Beta coefficients for
SNPs with Primary GWAS P,1E-04. CARE and ACRN P-values
are 1-sided based on the direction in CAMP/LOCCS/LODO/
Sepracor. CAMP/LOCCS/LODO/Sepracor reference allele was
minor allele as shown in Table 1. SE=Standard Error for
corresponding Beta coefficient. Rsq=MACH R-squared value for
imputed SNP. Combined P-values were obtained using the Liptak
method, with weights proportional to population size.
(DOCX)
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Rsq=MACH R-squared value for imputed SNP.
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Table S4 Primary GWAS 1000GP Imputed SNP P-values and
Beta coefficients for SNPs with P,1E-05. CARE and ACRN P-
values are 1-sided based on the direction in CAMP/LOCCS/
LODO/Sepracor. SE=Standard Error for corresponding Beta
coefficient. Combined P-values were obtained using the Liptak
method, with weights proportional to population size.
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Table S5 SARP Replication Results for SNPs with Primary
GWAS P,1E-04. P-values are 1-sided based on the direction in
CAMP/LOCCS/LODO/Sepracor. MAF=minor allele frequen-
cy.
(DOCX)
Table S6 Unadjusted P-values and log fold-change quantifying
differential expression of SPATS2L and SPATS2 probes for GEO
dataset GSE13168, in which human ASM cell lines expressing a
PKA inhibitor vs. a GFP control were compared at baseline and
when stimulated with IL1b, EGF, or both.
(DOCX)
Table S7 Primary GWAS 1000GP Imputed SNP details for
SNPs that have nominally significant p-values (,0.05) in, or within
50,000 KB of, genes (i.e. ADRB2, ADCY9, CRHR2, ARG1)
previously identified as being associated with BDR. There were
no such SNPs near ADRB2. MAF=Minor Allele Frequency.
Rsq=MACH R-squared value for imputed SNP.
(DOCX)
Table S8 Primary GWAS 1000GP Imputed SNP P-values and
Beta coefficients for SNPs that have nominally significant p-values
(,0.05), and are in, or within 50,000 KB of, genes (i.e. ADRB2,
ADCY9, CRHR2, ARG1) previously identified as being associated
with BDR. There were no such SNPs near ADRB2. CARE and
ACRN P-values are 1-sided based on the direction in CAMP/
LOCCS/LODO/Sepracor. SE=Standard Error for correspond-
ing Beta coefficient. Combined P-values were obtained using the
Liptak method, with weights proportional to population size.
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